Advanced nanoparticles help fight difficult cancers

By The Science Advisory Board staff writers

October 28, 2022 -- University of Chicago (UChicago) researchers are using tiny molecules called advanced nanoparticles to deliver compounds that suppress tumor growth and metastasis. The study, published October 27 in the journal Nature Nanotechnology, holds promise for treating difficult cancers.

Nanoparticles can be built with different materials in various shapes -- including crystal-like structures or capsules with enclosed contents. Nanoparticles' irregular vasculature helps trap their drugs within tumors, precisely where needed. The researchers formulated an advanced nanoparticle that carries a bacteria-derived compound to target STING (stimulator of interferon genes complex) -- a potent immune system pathway.

The new particles, called nanoscale coordination polymers (NCPs), have a non-toxic zinc phosphate core surrounded by lipid layers and can be engineered for controlled release. The researchers loaded the NCPs with the nucleotide cyclic dimeric adenosine monophosphate (CDA) -- a bit of DNA bacteria generated when invading a host. Its appearance, via either infection or nanoparticle, triggers the STING pathway and the host's immune response.

This immune response suppressed tumor growth and prevented metastasis in several cancers. It disrupted endothelial cells in the tumors' blood vessels, increasing CDA deposition. Further, macrophages that infiltrated tumors had an enhanced ability to present antigens marking them for attack. Both pancreatic tumors and gliomas became more susceptible to treatment.

UChicago professor and co-author Dr. Ralph Weichselbaum said in a statement that there is currently an unmet medical need to treat intractable tumors.

"That's the brilliant part of these nanoformulations. We were able to encapsulate a STING agonist that is extremely potent and promotes both innate and adaptive immunity," Weichselbaum said.

Co-author Wenbin Lin, PhD, chemistry professor at UChicago, formed the startup Coordination Pharmaceuticals to develop NCPs.

"The technology is versatile, and we are exploring ways to optimize formulations to take more NCP candidates into clinical trials," Lin said.

NCI awards researchers $2M grant to reverse drug resistance in lung cancer
University of Missouri researchers were awarded a $2.35 million grant from the National Cancer Institute (NCI) to help overcome drug resistance in non-small...
Nanoparticles enhance effect of brain stimulation on stroke recovery in rats
Combining nasally administered nanoparticles and noninvasive brain stimulation improves the recovery of ischemic stroke in rats, according to researchers...
Oral delivery of lipid nanoparticles effective for ulcerative colitis in mice
Georgia State University researchers have discovered a new way to treat ulcerative colitis -- oral delivery of lipid nanoparticles that target the colon...
Nanoparticles protect mice from blood vessel rupture, offers potential therapy for abdominal aortic aneurysms in humans
Administration of small interfering RNA nanoparticles has protected mice from sudden death due to the rupture of a major blood vessel in the abdomen,...
Analysis of nanoparticles, cancer cells could aid development of nanoparticle-based drugs
Researchers have identified biomarkers that predict whether different types of cancer cells will take up specific nanoparticles, potentially helping to...

Copyright © 2022

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter